News Search Results
Jan 06, 2026, 12:03 ET Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in
More news about: Espervita Therapeutics, Inc.
Jan 06, 2026, 12:00 ET National Student Leadership Conference and IEEE Partner to Advance Engineering & Technology Education for High School Students
NSLC's long-standing engineering and technology programs. Beginning Summer 2026, students enrolled in NSLC's Aerospace, Artificial Intelligence, Biotechnology, Cybersecurity, and Engineering programs will benefit from IEEE's global expertise in STEM education and curriculum design."We
More news about: National Student Leadership Conference
Jan 06, 2026, 11:18 ET How Does Community-Based Research Deliver Faster Results and Greater Access? Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 06, 2026, 11:11 ET Enhancing Clinical Efficiency Through Master Protocol Trial Design, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 06, 2026, 11:02 ET Merchant & Gould Opens Boston Office, Strengthening Its Depth and Breadth
broader support," said Timbers. "The firm's national platform, combined with our team's strengths, particularly in high-growth sectors such as biotechnology and software, creates a powerful synergy that benefits clients at every stage of the innovation lifecycle." Merchant has experienced rapid
More news about: Merchant & Gould
Jan 06, 2026, 11:00 ET Novoron Bioscience Awarded $2.5 Million NIH/NIA SBIR Grant to Accelerate Alzheimer's Drug Discovery with Human Brain Organoids
SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Novoron Bioscience, a San Diego-based biotechnology company developing therapies for neurodegenerative diseases and neurological injury, has received a $2.5 million Small Business Innovation Research
More news about: Novoron Bioscience
Jan 06, 2026, 10:50 ET ANSI Launches U.S. Standards Strategy 2025: A Blueprint for American Competitiveness in the 21st Century
emerging technologies and investment in the full standards ecosystem."The technologies defining this decade—artificial intelligence, biotechnology, quantum computing—all depend on standards," said Dr. Laurie E. Locascio, ANSI president and CEO. "This strategy positions American companies and
More news about: American National Standards Institute
Jan 06, 2026, 10:44 ET NanoMosaic Appoints Dr. Anne Marie Morse as Chairwoman of Newly Formed Clinical Advisory Board
role in digital transformation initiatives at Geisinger. She has advised and served as a principal investigator across numerous pharmaceutical and biotechnology organizations and is a widely recognized educator and patient advocate.About NanoMosaic Inc.NanoMosaic is a next-generation
More news about: NanoMosaic
Jan 06, 2026, 10:44 ET Forced Air Warming Market expected to generate a revenue of USD 2,580.89 Million by 2032, globally, at 6.81% CAGR: Verified Market Research®
Transplantation, Cell-Based Research, Cancer Research, Drug Development), By End-User (Hospitals, Research And Academic Institutes, Pharmaceutical And Biotechnology Companies, Organ Procurement Organizations), By Geographic Scope And Forecast
More news about: Verified Market Research
Jan 06, 2026, 10:30 ET Cell Culture Reagents Market worth $8.95 billion by 2030 | MarketsandMarkets™
https://www.marketsandmarkets.com/requestsampleNew.asp?id=52737241By end user, the pharmaceutical & biotechnology companies segment is expected to be the largest segment in the cell culture reagents market.the market for cell culture reagents has been segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories,
More news about: MarketsandMarkets
Jan 06, 2026, 09:30 ET Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announced dosing of the first patient
More news about: Bambusa Therapeutics, Inc.
Jan 06, 2026, 09:00 ET HighVista Strategies Appoints Three Senior Leaders as Partners
span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-asset alternatives.Media Contacts Prosek Partners
More news about: HighVista Strategies LLC
Jan 06, 2026, 09:00 ET AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at
More news about: Amgen
Jan 06, 2026, 09:00 ET Vella Bioscience Appoints Industry Innovator Joy Allen-Altimare as President, Accelerating a New Era of Femtech, Hormonal Health, and Science-Led Sexual Wellness
FemTech innovator dedicated to advancing women's sexual, hormonal, and intimate wellness through rigorous science and proprietary biotechnology. Built on scientific rigor and developed by the same team behind Viagra® and Cialis®, Vella addresses critical gaps in women's
More news about: Vella Bioscience
Jan 06, 2026, 09:00 ET The Reeve Foundation and Spinal Research Award New Grants to Advance Traumatic Spinal Cord Injury Treatments
Novoron Bioscience, Inc., a preclinical biotechnology company focused on therapies for brain and spinal cord injuries, will study the safety of its investigational drug NOVO-120 as it prepares for future
More news about: Christopher & Dana Reeve Foundation
Jan 06, 2026, 08:53 ET NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
late-phase clinical trials. His most recent roles as CMO included positions at Rafael Holding, Inc., a healthcare investment, family office, and biotechnology company, and at Oncorus, Inc., a biopharmaceutical company developing an intratumorally delivered viral immunotherapy for cancer. Earlier in his
More news about: NanOlogy LLC
Jan 06, 2026, 08:34 ET GBI Biomanufacturing Announces the Appointment of Jesse McCool, Ph.D. as President
GBI Biomanufacturing is a U.S.-based biopharmaceutical contract development and manufacturing organization (CDMO) supporting biotechnology and pharmaceutical companies with integrated services across biologics development and cGMP manufacturing. With capabilities spanning drug substance
More news about: GBI Biomanufacturing
Jan 06, 2026, 08:30 ET 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week
Morgan Healthcare Conference week, the Forum brings together the scientists, innovators, investors and decision-makers to discuss the future of biotechnology – where discovery, computation and therapeutic development converge to turn scientific possibilities into patient impact.Under the theme
More news about: GenScript USA
Jan 06, 2026, 08:30 ET ABS Bio Acquires Cureline, Broadening Access to Biospecimens & Streamlining Execution from End to End
"3BC") portfolio company and a leader in biospecimen sourcing, cell culture services, and biorepository solutions for the global pharmaceutical and biotechnology industry, has acquired Cureline, Inc. ("Cureline"), a leading provider of specimen procurement and histology services to the pharmaceutical and
More news about: 3 Boomerang Capital
Jan 06, 2026, 08:00 ET Braveheart Bio to Present at 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that the company will participate
More news about: Braveheart Bio
Jan 06, 2026, 08:00 ET Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding
for fostering international collaboration between the UK and Canada.About Chromatin BioChromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted eukaryotic gene control systems. Its proprietary platform, chromatinLENS TM,
More news about: CHROMATIN BIOSCIENCE LTD
Jan 06, 2026, 08:00 ET Stealth BioTherapeutics Provides Commercial and R&D Pipeline Update and Outlines 2026 Strategic Priorities
Jan. 6, 2026 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today provided
More news about: Stealth BioTherapeutics Inc.
Jan 06, 2026, 07:19 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis
HOUSTON, Jan. 6, 2026 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf, regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced that the U.S.
More news about: Cellenkos, Inc.
Jan 06, 2026, 03:30 ET LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease
CAMBRIDGE, England, Jan. 6, 2026 /PRNewswire/ -- LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease
More news about: LoQus23 Therapeutics
Jan 05, 2026, 19:00 ET Xellar and WOOJUNG BIO Announce Multi-Year Strategic Partnership to Advance AI-Enabled Hybrid Human Organ-on-a-Chip (OoC)-Animal Preclinical Platforms
multi-year strategic collaboration agreement with WOOJUNG BIO Co., Ltd. ("WOOJUNG BIO"; KOSDAQ: 215380), a Korea-listed biotechnology company with strong capabilities in translational research and life sciences services. Through this collaboration, the two companies will
More news about: Xellar Biosystems